Diagnostic accuracy stressed in UK COPD (chronic obstructive pulmonary disease) guideline:
This article was originally published in Clinica
Executive Summary
Spirometry, X-ray, CT and blood count feature in new NHS guidelines on the management of chronic obstructive pulmonary disease (COPD), which aim to improve the accuracy of diagnosis and the care of this under-recorded condition. The Guidelines issued by the National Institute for Clinical Excellence (NICE) and the National Collaborating Centre for Chronic Conditions recommend that initial diagnoses based on spirometric testing be confirmed using chest radiography and a full blood count to identify anaemia and polycythaemia. A CT scan should be used to further investigate symptoms that seem disproportionate to spirometric impairment. Noninvasive ventilation is recommended as the treatment of choice for persistent hyperbaric ventilatory failure. Some 900,000 people have been diagnosed with COPD in England and Wales, where it is responsible for some 30,000 deaths a year, making it the fifth most common cause of death. There may be as many undiagnosed cases as those recorded, NICE experts believe.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.